Literature DB >> 22810252

Metabolic encephalopathies in the critical care unit.

Jennifer A Frontera1.   

Abstract

PURPOSE OF REVIEW: This article summarizes the most common etiologies and approaches to management of metabolic encephalopathy. RECENT
FINDINGS: Metabolic encephalopathy is a frequent occurrence in the intensive care unit setting. Common etiologies include hepatic failure, renal failure, sepsis, electrolyte disarray, and Wernicke encephalopathy. Current treatment paradigms typically focus on supportive care and management of the underlying etiology. Directed therapies that target neurochemical and neurotransmitter pathways that mediate encephalopathy are not currently available and represent an important area for future research. Although commonly thought of as reversible neurologic insults, delirium and encephalopathy have been associated with increased mortality, prolonged length of stay and hospital complications, and worse long-term cognitive and functional outcomes.
SUMMARY: Recognition and treatment of encephalopathy is critical to improving outcomes in critically ill patients.

Entities:  

Mesh:

Year:  2012        PMID: 22810252     DOI: 10.1212/01.CON.0000415431.07019.c2

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  10 in total

Review 1.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.

Authors:  Adeel S Zubair; Lindsay S McAlpine; Tova Gardin; Shelli Farhadian; Deena E Kuruvilla; Serena Spudich
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

2.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 3.  Neurologic Complications in the Intensive Care Unit.

Authors:  Clio Rubinos; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

4.  Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.

Authors:  Jennifer A Frontera; Allal Boutajangout; Arjun V Masurkar; Rebecca A Betensky; Yulin Ge; Alok Vedvyas; Ludovic Debure; Andre Moreira; Ariane Lewis; Joshua Huang; Sujata Thawani; Laura Balcer; Steven Galetta; Thomas Wisniewski
Journal:  Alzheimers Dement       Date:  2022-01-13       Impact factor: 16.655

Review 5.  Septic encephalopathy.

Authors:  Marek Ziaja
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

6.  An Intriguing Case of Acute Encephalopathy: Lesson Learned from a Constipated Man.

Authors:  Munish Sharma; Humayun Anjum; Chinthaka P Bulathsinghala; Palla Rivi De Silva; Salim Surani
Journal:  Cureus       Date:  2020-01-16

Review 7.  Murine-β-coronavirus-induced neuropathogenesis sheds light on CNS pathobiology of SARS-CoV2.

Authors:  Debanjana Chakravarty; Jayasri Das Sarma
Journal:  J Neurovirol       Date:  2021-02-05       Impact factor: 2.643

Review 8.  SARS-CoV-2 Neuronal Invasion and Complications: Potential Mechanisms and Therapeutic Approaches.

Authors:  Olivia Swain; Sofia K Romano; Ritika Miryala; Jocelyn Tsai; Vinnie Parikh; George K E Umanah
Journal:  J Neurosci       Date:  2021-06-23       Impact factor: 6.167

9.  Do Triphasic Waves and Nonconvulsive Status Epilepticus Arise From Similar Mechanisms? A Computational Model.

Authors:  Sophie Ligtenstein; Jiangling Song; Jin Jin; Haoqi Sun; Luis Paixao; Sahar Zafar; M Brandon Westover
Journal:  J Clin Neurophysiol       Date:  2021-09-01       Impact factor: 2.590

10.  Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19.

Authors:  Jennifer A Frontera; Kara Melmed; Taolin Fang; Andre Granger; Jessica Lin; Shadi Yaghi; Ting Zhou; Ariane Lewis; Sebastian Kurz; D Ethan Kahn; Adam de Havenon; Joshua Huang; Barry M Czeisler; Aaron Lord; Sharon B Meropol; Andrea B Troxel; Thomas Wisniewski; Laura Balcer; Steven Galetta
Journal:  Neurocrit Care       Date:  2021-03-16       Impact factor: 3.210

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.